
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Chris Hatwig, MS, FASHP of Apexus discusses what HRSA policy updates, including 340B "mega guidance," are poised to affect health-system pharmacists.
Chris Hatwig, MS, FASHP of Apexus discusses what HRSA policy updates, including 340B "mega guidance," are poised to affect health-system pharmacists.
This video was shot at ASHP's Summer Meetings and Exposition in Denver in June 2015.






